Search Results for “Clinical Trial” – Page 60 – media

US study reveals interferon combinations cause lupus symptoms and affect treatment

The autoimmune disease, which affects 1.5 million people in the US, causes the body’s immune system to attack its own tissues Researchers from Johns Hopkins Medicine have revealed that certain combinations of antiviral proteins are responsible for symptoms and affect treatment outcomes for patients with lupus. Published in Cell Reports Medicine, researchers suggest that the findings could lead to changes in how clinicians treat patients with the condition. Affecting up to 1.5 million people in the US, lupus is a chronic autoimmune disease that causes the body’s immune system to attack its own tissues. In clinical trials for lupus treatments designed to suppress interferon I, researchers observed that patients’ conditions failed to improve, despite genetic testing showing high interferon I levels prior to treatment. The team predicted that two other interferon groups, interferon II and interferon III, could be the reason for poor treatment responses in lupus patients. Looking at ...
- Source: drugdu
- 117
- May 17, 2024
First Patient Dosed for MRCT Phase 3 Study on First-Line mCRC of Henlius Anti-PD-1 mAb Serplulimab

Shanghai, China, May 15, 2024 – Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient has been dosed in the phase 3 stage of the international multi-centre clinical trial (ASTRUM-015) of the company’s self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination with bevacizumab and chemotherapy in patients with metastatic colorectal cancer (mCRC). The leading principal investigator is Professor Rui-Hua Xu from Sun Yat-sen University Cancer Center and State Key Laboratory of Oncology in South China. Currently, for mCRC patients, immunotherapies have been proven to bring hope to patients with mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) but have not yet shown meaningful positive outcomes in those with proficient mismatch repair (pMMR)/ microsatellite stable (MSS), and there is no immunotherapy approved globally for the first-line treatment of mCRC. HANSIZHUANG is expected to become the world’s first anti-PD-1 mAb for the first-line treatment of mCRC. Colorectal cancer (CRC) is one of the most ...
- Source: drugdu
- 71
- May 17, 2024
Answering the Call

From Big Pharma to biotech—and a globe-spanning journey along the way—Yvonne Greenstreet, this year’s Healthcare Businesswomen’s Association Woman of the Year, is right where she wants to be: leading efforts to advance “bold ideas” in RNAi therapeutics into life-changing gains for patients. Yvonne Greenstreet, CEO, Alnylam It’s no surprise that Yvonne Greenstreet is winning awards. On Jan. 9, the Healthcare Businesswomen’s Association (HBA) announced the Alnylam CEO as its 2024 Woman of the Year. In the release, the HBA said that Greenstreet had earned the honor through her “notable and remarkable commitment and valuable contributions to women in the healthcare ecosystem.” It went on to describe Greenstreet as a trailblazer, advocate, and a true leader. Specifically, Greenstreet’s leadership at Alnylam, an RNA interference (RNAi) therapeutics company, was recognized. Since being appointed CEO in October 2021, she has helped steer Alnylam to being named one of Fortune’s Best Workplaces for Women. ...
- Source: drugdu
- 69
- May 14, 2024
Avoiding the Digital Age is Hurting Research Efforts

Mike Hollan Pharmaceutical ExecutivePharmaceutical Executive: May 2024 Mike Hollan, Assistant Managing Editor, Pharmaceutical Executive When it comes to developing new drugs and therapies, there is obviously nothing more important than data. Countless bits of data are collected for each medication before it hits the market, and researchers continue to collect data after that. Even before the modern technology boom, data was a key component of the life sciences industry. In the modern world, data is more valuable than ever. New technologies, such as AI and machine learning algorithms, are capable or collecting, sorting, and analyzing bits of data at a faster rate than ever before. Researchers across almost every industry are seeing the benefits and discovering new ways to innovate based on these discoveries. In the life sciences industry, this data is being used for everything from drug development, market analysis, and even scheduling sales reps calls. It’s undeniable that ...
- Source: drugdu
- 71
- May 14, 2024
Introduced GLP-1 product Simeglutide Injection

Recently, Tong Hua Dong Bao Pharmaceutical Company Limited (“Tong Hua Dong Bao” or the “Company”) signed a Commercialization License and MAH Cooperation Agreement (“Commercialization License and MAH Cooperation Agreement”) on the GLP-1 product simelglutide injection (“Simelglutide Injection”) with Beijing Quality Peptide Bio-pharmaceutical Technology Co. (hereinafter referred to as “QPBio”) entered into the Commercialization License and MAH Cooperation Agreement (hereinafter referred to as the “Agreement”) in relation to the GLP-1 product, Simeglutide Injection. Pursuant to the Agreement, the Company will obtain the exclusive commercialization rights and interests in Mainland China for ZT001 Simeglutide Injection (indication: blood glucose control in adults with type 2 diabetes mellitus) (the “Collaboration Product”), which is a clinical product under development by Plasmapeptide Biologics, as well as the right to co-develop the overseas market. The Cooperative Product has completed the Phase I clinical trial for the indication of type 2 diabetes mellitus in Mainland China and has ...
- Source: drugdu
- 111
- May 10, 2024
Securing Audience Measurement in Pharma Marketing

Ray Kingman The industry must find a way to balance consumer privacy and a return on investment in pharma marketing. Promoting advances in pharmaceuticals is full of challenges. From recruiting clinical trial participants, to engaging patients with their permission at the point of care, to creating brand lift and awareness, the marketing landscape for pharma presents both logistical and regulatory obstacles when it comes to constructing and executing a successful marketing program. Identity, and how it is managed, presents special challenges for audience targeting and especially measurement of campaign performance in an evolving identity resolution environment. Across our multi-channel, multi-platform and multi-media landscape the signals that avail us for targeting and measurement are often impeded by the requirement to block or exercise restraint when it comes to sensitive data and patient privacy rights. Building privacy-compliant audiences for pharma campaigns takes special care, but identifying audience engagement that measures campaign outcomes ...
- Source: drugdu
- 84
- May 10, 2024
Lantern Pharma and Oregon partner to develop cancer treatment

Lantern Pharma has entered into a partnership with Oregon Therapeutics for optimising the development of the cancer drug candidate, XCE853, through an AI-driven approach. XCE853 is an inhibitor of protein disulfide isomerase (PDI). The partnership will utilise RADR AI platform of Lantern to identify biomarkers and efficacy-linked signatures of XCE853 for precision development across solid tumours. Furthermore, this alliance will identify biomarker signatures that can aid in stratifying tumours that are most responsive to the drug and facilitate in the clinical development and patient selection in the future. Oregon focuses on developing XCE853 for a range of cancer indications, including drug-resistant ovarian and pancreatic cancers, certain haematological cancers, and several paediatric cancers, such as central nervous system (CNS) cancers. The collaboration aims to harness computational tools, including machine learning and large-scale molecular analysis, to streamline the development process. The partnership will integrate and interrogate a vast array of molecular, genetic, ...
- Source: drugdu
- 68
- May 9, 2024
Henlius Dual HER2 Blockade Therapy Receives Phase 3 MRCT IND Approval from U.S. FDA

Shanghai, China, May 6, 2024-Shanghai Henlius Biotech, Inc. (2696.HK) announced that the investigational new drug application (IND) for phase 3 international multicenter clinical study of Henlius’ novel anti-HER2 mAb, HLX22, in combination with trastuzumab and chemotherapy for the first-line treatment of HER2-positive advanced gastric cancer has been approved by the United States Food and Drug Administration (FDA). As of now, no similar dual HER2 blockade therapy for the treatment of HER2-positive gastric cancer has received approval for commercialization globally. Until now, gastric/gastroesophageal junction (G/GEJ) cancer still constitutes a major global health problem. Globally, there were around 1 million cases in 2022. G/GEJ cancer generally carries a poor prognosis since it is often diagnosed at an advanced stage, with a 5-year relative survival rate of only 6%. The reported rates of HER2 positivity in patients with gastric cancer range from 12% to 23%, and the prognosis for patients with HER2-positive disease ...
- Source: drugdu
- 69
- May 8, 2024
Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint

BEIJING and SHANGHAI and BOSTON, April 30, 2024 /PRNewswire/ — Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online. Prof. Yuankai Shi, chief physician of Cancer Hospital Chinese Academy of Medical Sciences, the lead principal investigator of this clinical trial, presented the data in the form of an online oral presentation (Abstract 468214). The efficacy data showed that among second-line non-small cell lung cancer patients receiving monotherapy treatment, the confirmed objective response rate (cORR) was 47.9% (56/117), including 4 patients achieved a complete response (CR) and 36 patients with tumor reduction exceeding 50%. Disease control rate (DCR) was 86.3%. The median progression-free survival (mPFS) was 8.2 months, and median overall survival (mOS) was 13.6 months. The median duration of response (mDoR) has not been reached:6-month and 12-month ...
- Source: drugdu
- 85
- May 6, 2024
Urine Test to Revolutionize Lyme Disease Testing

Lyme disease is the most common animal-to-human transmitted disease in the United States, with around 476,000 people diagnosed and treated annually, and its incidence has been increasing. If not addressed promptly and effectively, those affected may experience persistent symptoms known as Post-Treatment Lyme Disease Syndrome, which include issues with concentration and memory, dizziness, fatigue, body aches, depression, and sleep disturbances. Currently, the standard diagnostic approach involves an antibody blood test that detects the immune system’s response to the bacteria responsible for Lyme disease. Now, urine testing could revolutionize Lyme disease detection and diagnosis thanks to its many advantages over existing techniques. Researchers at George Mason University (Fairfax, VA, USA) have developed a urine test for Lyme disease that detects the Borrelia bacteria, which causes Lyme disease. This advancement allows for the confirmation of an infection shortly after a tick bite, leading to timely treatment and helping to avoid the ...
- Source: https://www.labmedica.com/molecular-diagnostics/articles/294801060/urine-test-to-revolutionize-lyme-disease-testing.html
- 96
- May 4, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.